Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12062288 | 0.87 | HSD11B1 (0.66) | HSD11B1LMNAGAAALDH1A1POLB | |
| SCHEMBL4636703 | 0.84 | ALDH1A1 (0.51) | HSD11B1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL4635004 | 0.82 | PKM (0.56) | LMNAGAAALDH1A1POLBCYP2C19 | |
| SCHEMBL4635774 | 0.79 | ALDH1A1 (0.47) | LMNAALDH1A1POLBCYP3A4CYP2C19 | |
| SCHEMBL4636596 | 0.79 | PKM (0.53) | LMNAALDH1A1POLBCYP3A4CYP2C19 | |
| SCHEMBL7904364 | 0.78 | CYP2C9 (0.52) | LMNAGAAALDH1A1POLBMEN1 | |
| SCHEMBL20772228 | 0.78 | LMNA (0.67) | HSD11B1LMNAGAAALDH1A1POLB | |
| SCHEMBL12061779 | 0.78 | HSD11B1 (0.71) | HSD11B1LMNAGAAALDH1A1POLB | |
| SCHEMBL12169350 | 0.78 | HSD11B1 (0.62) | HSD11B1LMNAGAAALDH1A1POLB | |
| SCHEMBL12786780 | 0.77 | HSD11B1 (1.00) | HSD11B1LMNAGAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | HSD11B1 251/4885LMNA 3634/4885GAA 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.